Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-BolusType 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial
- Author
- HELLER, Simon1 ; BUSE, John2 ; HUILING PEI12 ; BODE, Bruce13 ; FISHER, Miles3 ; GARG, Satish4 ; MARRE, Michel5 ; MERKER, Ludwig6 ; RENARD, Eric7 ; RUSSELL-JONES, David8 9 ; PHILOTHEOU, Areti10 ; FRANCISCO, Ann Marie Ocampo11
[1] University of Sheffield, Sheffield, United Kingdom
[2] University of North Carolina School of Medicine, Chapel Hill, NC, United States
[3] Glasgow Royal Infirmary, Glasgow, United Kingdom
[4] Barbara Davis Center for Childhood Diabetes, Aurora, CO, United States
[5] Hôpital Bichat-Claude Bernard, Assistance Publique des Hôpitaux de Paris, France
[6] Diabetes und Nierenzentrum, Dormagen, Germany
[7] Montpellier University Hospital, Montpellier, France
[8] Royal Surrey County Hospital, Surrey, United Kingdom
[9] University of Surrey, Surrey, United Kingdom
[10] University of Cape Town Private Academic Hospital, Cape Town, South Africa
[11] Novo Nordisk, Søborg, Denmark
[12] Novo Nordisk, Princeton, NJ, United States
[13] Atlanta Diabetes Associates, Atlanta, GA, United States
BEGIN Basal-Bolus Type 1 Trial Investigators - Source
Lancet (British edition). 2012, Vol 379, Num 9825, pp 1489-1497, 9 p ; ref : 24 ref
- CODEN
- LANCAO
- ISSN
- 0140-6736
- Scientific domain
- General medicine general surgery
- Publisher
- Elsevier, Kidlington
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Keyword (fr)
- Ciblage Cible Diabète de type 1 Etiquette Etude comparative Hypoglycémiant Injection bolus Insuline asparte Insuline glargine Maladie autoimmune Médecine Phase Randomisation Traitement Essai de non-infériorité Insuline à action lente Insuline à action rapide Endocrinopathie Immunopathologie
- Keyword (en)
- Targeting Target Type 1 diabetes Label Comparative study Hypoglycemic agent Bolus injection Insulin aspart Insulin glargine Autoimmune disease Medicine Phase Randomization Treatment Non-inferiority trial Endocrinopathy Immunopathology
- Keyword (es)
- Blancado Blanco Diabetes de tipo 1 Etiqueta Estudio comparativo Hipoglicemiante Inyección bolo Insulina asparta Insulina glargina Enfermedad autoinmune Medicina Fase Aleatorización Tratamiento Ensayo de no inferioridad Endocrinopatía Inmunopatología
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B21 Endocrinopathies / 002B21E Endocrine pancreas. Apud cells (diseases) / 002B21E01 Diabetes. Impaired glucose tolerance / 002B21E01A Etiopathogenesis. Screening. Investigations. Target tissue resistance
- Discipline
- Endocrinopathies Generalities in medical sciences
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 25810617
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1016/S0140-6736(12)60204-9 
https://dx.doi.org/10.1016/S0140-6736(12)60204-9
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0140-6736(12)60204-9\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:249:\"Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-BolusType 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Lancet (British edition)\";s:9:\"\u0000*\u0000stitle\";s:16:\"Lancet (Br. ed.)\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:3:\"379\";s:8:\"\u0000*\u0000issue\";s:4:\"9825\";s:8:\"\u0000*\u0000spage\";s:4:\"1489\";s:8:\"\u0000*\u0000epage\";s:4:\"1497\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0140-6736\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"HELLER\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Simon\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:11:{i:0;s:10:\"BUSE, John\";i:1;s:11:\"HUILING PEI\";i:2;s:11:\"BODE, Bruce\";i:3;s:13:\"FISHER, Miles\";i:4;s:12:\"GARG, Satish\";i:5;s:13:\"MARRE, Michel\";i:6;s:14:\"MERKER, Ludwig\";i:7;s:12:\"RENARD, Eric\";i:8;s:20:\"RUSSELL-JONES, David\";i:9;s:17:\"PHILOTHEOU, Areti\";i:10;s:27:\"FRANCISCO, Ann Marie Ocampo\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LANCAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:249:\"Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-BolusType 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial\";s:8:\"\u0000*\u0000place\";s:10:\"Kidlington\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0140-6736(12)60204-9\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:249:\"Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-BolusType 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Lancet (British edition)\";s:9:\"\u0000*\u0000stitle\";s:16:\"Lancet (Br. ed.)\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:3:\"379\";s:8:\"\u0000*\u0000issue\";s:4:\"9825\";s:8:\"\u0000*\u0000spage\";s:4:\"1489\";s:8:\"\u0000*\u0000epage\";s:4:\"1497\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0140-6736\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"HELLER\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Simon\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:11:{i:0;s:10:\"BUSE, John\";i:1;s:11:\"HUILING PEI\";i:2;s:11:\"BODE, Bruce\";i:3;s:13:\"FISHER, Miles\";i:4;s:12:\"GARG, Satish\";i:5;s:13:\"MARRE, Michel\";i:6;s:14:\"MERKER, Ludwig\";i:7;s:12:\"RENARD, Eric\";i:8;s:20:\"RUSSELL-JONES, David\";i:9;s:17:\"PHILOTHEOU, Areti\";i:10;s:27:\"FRANCISCO, Ann Marie Ocampo\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LANCAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:249:\"Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-BolusType 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial\";s:8:\"\u0000*\u0000place\";s:10:\"Kidlington\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0140-6736(12)60204-9\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0140-6736(12)60204-9\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:249:\"Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-BolusType 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Lancet (British edition)\";s:9:\"\u0000*\u0000stitle\";s:16:\"Lancet (Br. ed.)\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:3:\"379\";s:8:\"\u0000*\u0000issue\";s:4:\"9825\";s:8:\"\u0000*\u0000spage\";s:4:\"1489\";s:8:\"\u0000*\u0000epage\";s:4:\"1497\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0140-6736\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"HELLER\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Simon\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:11:{i:0;s:10:\"BUSE, John\";i:1;s:11:\"HUILING PEI\";i:2;s:11:\"BODE, Bruce\";i:3;s:13:\"FISHER, Miles\";i:4;s:12:\"GARG, Satish\";i:5;s:13:\"MARRE, Michel\";i:6;s:14:\"MERKER, Ludwig\";i:7;s:12:\"RENARD, Eric\";i:8;s:20:\"RUSSELL-JONES, David\";i:9;s:17:\"PHILOTHEOU, Areti\";i:10;s:27:\"FRANCISCO, Ann Marie Ocampo\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LANCAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:249:\"Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-BolusType 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial\";s:8:\"\u0000*\u0000place\";s:10:\"Kidlington\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0140-6736(12)60204-9\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:249:\"Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-BolusType 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Lancet (British edition)\";s:9:\"\u0000*\u0000stitle\";s:16:\"Lancet (Br. ed.)\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:3:\"379\";s:8:\"\u0000*\u0000issue\";s:4:\"9825\";s:8:\"\u0000*\u0000spage\";s:4:\"1489\";s:8:\"\u0000*\u0000epage\";s:4:\"1497\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0140-6736\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"HELLER\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Simon\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:11:{i:0;s:10:\"BUSE, John\";i:1;s:11:\"HUILING PEI\";i:2;s:11:\"BODE, Bruce\";i:3;s:13:\"FISHER, Miles\";i:4;s:12:\"GARG, Satish\";i:5;s:13:\"MARRE, Michel\";i:6;s:14:\"MERKER, Ludwig\";i:7;s:12:\"RENARD, Eric\";i:8;s:20:\"RUSSELL-JONES, David\";i:9;s:17:\"PHILOTHEOU, Areti\";i:10;s:27:\"FRANCISCO, Ann Marie Ocampo\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LANCAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:249:\"Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-BolusType 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial\";s:8:\"\u0000*\u0000place\";s:10:\"Kidlington\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S0140-6736(12)60204-9\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:249:\"Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-BolusType 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial\";s:9:\"\u0000*\u0000jtitle\";s:24:\"Lancet (British edition)\";s:9:\"\u0000*\u0000stitle\";s:16:\"Lancet (Br. ed.)\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:3:\"379\";s:8:\"\u0000*\u0000issue\";s:4:\"9825\";s:8:\"\u0000*\u0000spage\";s:4:\"1489\";s:8:\"\u0000*\u0000epage\";s:4:\"1497\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0140-6736\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"HELLER\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Simon\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:11:{i:0;s:10:\"BUSE, John\";i:1;s:11:\"HUILING PEI\";i:2;s:11:\"BODE, Bruce\";i:3;s:13:\"FISHER, Miles\";i:4;s:12:\"GARG, Satish\";i:5;s:13:\"MARRE, Michel\";i:6;s:14:\"MERKER, Ludwig\";i:7;s:12:\"RENARD, Eric\";i:8;s:20:\"RUSSELL-JONES, David\";i:9;s:17:\"PHILOTHEOU, Areti\";i:10;s:27:\"FRANCISCO, Ann Marie Ocampo\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LANCAO\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:249:\"Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-BolusType 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial\";s:8:\"\u0000*\u0000place\";s:10:\"Kidlington\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
